Showing results (111-120 of 122) with videos related to
Sort By:
Pageof 13
Human Genetics|May 6, 2026
A novel splice site variant in DEGS1 leads to aberrant splicing and loss of DEGS1 enzyme activity, a VUS resolvedHolly C Beale, Victor Tse, Joanna Y Lee, et al.Cell Reports|September 27, 2025
IGF2BP3 redirects glycolytic flux to promote one-carbon metabolism and RNA methylationGunjan Sharma, Martin Gutierrez, Anthony E Jones, et al.Medrxiv : the Preprint Server for Health Sciences|April 29, 2025
A novel splice site variant in <i>DEGS1</i> leads to aberrant splicing and loss of DEGS1 enzyme activity, a VUS resolvedHolly C Beale, Victor Tse, Joanna Y Lee, et al.Cancer Research|June 4, 2024
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant CancersPatricia J Keller, Elizabeth J Adams, Rentian Wu, et al.Nature Medicine|July 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim resultsMartin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.Journal for Immunotherapy of Cancer|June 29, 2023
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomasAndrew L Coveler, David C Smith, Tycel Phillips, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as BiomarkersNeal Ready, Matthew D Hellmann, Mark M Awad, et al.International Journal of Molecular Sciences|March 13, 2024
<i>PRPH2</i>-Related Retinal Dystrophies: Mutational Spectrum in 103 Families from a Spanish CohortLidia Fernández-Caballero, Inmaculada Martín-Merida, Fiona Blanco-Kelly, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLCScott J Antonia, Ani Balmanoukian, Julie Brahmer, et al.Cancer Discovery|August 8, 2024
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 StudyJustin F Gainor, Manish R Patel, Jeffrey S Weber, et al.Pageof 13